Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children who were first diagnosed between 1 year old and 18 years old, and who are younger than 21 years old at the time of joining the trial.
• People whose general health and ability to carry out daily activities meets a minimum level, as measured by standard scoring tools used by doctors.
• People (or their parents or legal guardians) who are able and willing to give written consent to take part, following local guidelines.
• People whose cancer has been tested using detailed genetic and cellular analysis at the time of relapse or treatment resistance, before joining the trial — some exceptions may be considered after discussion with the trial sponsor (confirm with trial site).
• People whose cancer shows specific changes in a biological pathway called IL-7R and/or JAK-STAT signalling — this includes a range of specific genetic changes in genes such as CRLF2, EPOR, JAK1/2/3, IL7R, SH2B3, JAK2, USP9X, STAT5B, DNM2, and PTPN2, among others (confirm with trial site for the full list).
• People whose kidneys are working well enough, based on blood tests taken within 48 hours before starting treatment.
• People whose liver is working well enough based on blood tests, although exceptions may be considered if liver problems are caused by the underlying disease (confirm with trial site).
• People whose heart is functioning well enough, based on an echocardiogram or similar scan, and who do not have significant abnormal heart rhythms or a prolonged electrical signal in the heart (called QT prolongation).

Who may not be able to join:

• People who are pregnant, or who test positive for pregnancy within 7 days before starting treatment.
• People who are sexually active and are not willing to use a highly effective form of contraception during the trial and for 6 months after finishing treatment.
• People who are currently breastfeeding.
• People who have stomach or bowel problems that could affect how oral medications are absorbed by the body, such as severe nausea, vomiting, diarrhoea, or conditions affecting nutrient absorption.
• People whose cancer has specific known genetic changes that make it resistant to one of the study drugs (a JAK inhibitor), including certain JAK1 and JAK2 mutations.
• People whose cancer has specific known genetic changes that make it resistant to another study drug called venetoclax, such as certain BCL2 mutations.
• People who have had a serious allergic or hypersensitivity reaction to any of the study drugs or closely related medications, including certain chemotherapy drugs and steroids.
• People with a known active hepatitis infection, HIV infection, or any other infection that is not well controlled.
• People with another serious illness that, in the treating doctor's opinion, would prevent safe participation in the trial.
• People who are unable or unwilling to follow the study procedures.
• People who have previously received both ruxolitinib and venetoclax together — people who have received either drug on its own may still be considered eligible (confirm with trial site).
• People currently taking, or who would need to take during the trial, certain medications or herbal preparations that are not permitted, including some antiviral, antifungal, antibiotic, antipsychotic, and antidepressant medicines, as well as others that affect how the study drugs are processed in the body or affect heart rhythm (confirm with trial site for the full list).
• People who have eaten grapefruit, grapefruit products, Seville oranges (including certain marmalades), or starfruit within 72 hours before their first dose of the study drug.
• People who still have significant side effects (grade 2 or higher) from previous cancer treatments, unless the treating doctor considers these not to be clinically relevant given what is known about the study drugs.
• People with active acute graft-versus-host disease (a complication following bone marrow transplant) of any severity, or moderate-to-severe chronic graft-versus-host disease, or who are currently taking medication to treat or prevent this complication.
• People who received immune-suppressing medication after a bone marrow transplant within one month of joining the trial.
• People with a history of certain bone conditions — such as brittle bone disease, rickets, bone infections, or similar disorders — that existed before their cancer diagnosis.
• People with a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML).
• People with a history of growth problems related to hormone or kidney conditions that existed before their cancer diagnosis.
• People with clinically active tuberculosis.
• People who have not waited long enough since their last cancer treatment before starting the trial — specific waiting periods apply depending on the type of treatment received, including chemotherapy, radiotherapy, stem cell transplant, immunotherapy, antibody treatments, and major surgery (confirm with trial site for the exact timeframes that apply).

Important: Always verify eligibility with the trial site directly before applying.